發(fā)布時(shí)間：2018-06-26 04:04

  本文選題：西洛他唑 + 阿司匹林　； 參考：《中國臨床藥理學(xué)雜志》2017年03期

【摘要】：目的觀察西洛他唑片聯(lián)合阿司匹林片和氯吡格雷片對(duì)老年腦血管疾病神經(jīng)介入后抗血栓作用的臨床療效及安全性。方法將39例進(jìn)行腦血管疾病神經(jīng)介入術(shù)患者隨機(jī)分為對(duì)照組11例和試驗(yàn)組28例。對(duì)照組予以口服阿司匹林300 mg qd+口服氯吡格雷75 mg qd。試驗(yàn)組在對(duì)照組治療的基礎(chǔ)上,予以口服西洛他唑200 mg qd。2組患者均從術(shù)前1周服藥至術(shù)后6個(gè)月。比較2組患者的臨床療效、血小板聚集率及血流動(dòng)力學(xué)指標(biāo),以及藥物不良反應(yīng)的發(fā)生情況。結(jié)果治療后,試驗(yàn)組和對(duì)照組的總有效率分別為85.71%(24/28例)和54.55%(6/11例),差異有統(tǒng)計(jì)學(xué)意義(P0.05)。治療后,試驗(yàn)組和對(duì)照組的血小板聚集率分別為(44.57±8.44)%,(56.83±11.46)%;全血黏度切變率分別為(2.92±1.09)%,(3.96±1.32)%;血漿黏度分別為(1.20±0.32),(1.51±0.43)m Pa·s;相對(duì)血液黏度切變率分別為(2.18±0.28)%,(2.50±0.41)%;血細(xì)胞比容分別為(0.38±0.06)%,(0.48±0.06)%;纖維蛋白原分別為(2.83±1.04),(3.29±1.26)g·L~(-1),差異均有統(tǒng)計(jì)學(xué)意義(P0.05)。2組患者發(fā)生的藥物不良反應(yīng)以頭痛和胃腸道反應(yīng)為主,且試驗(yàn)組和對(duì)照組的藥物不良反應(yīng)發(fā)生率分別為21.43%和27.27%,差異無統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論西洛他唑片聯(lián)合阿司匹林片和氯吡格雷片對(duì)老年腦血管疾病神經(jīng)介入后抗血栓作用顯著,且不增加藥物不良反應(yīng)的發(fā)生率。
[Abstract]:Objective to observe the clinical efficacy and safety of cilostazol tablets combined with aspirin tablets and clopidogrel tablets in the treatment of senile cerebrovascular diseases after neurovascular intervention. Methods 39 patients with cerebrovascular disease were randomly divided into control group (n = 11) and experimental group (n = 28). The control group was treated with aspirin 300 mg QD and clopidogrel 75 mg QD. On the basis of the treatment in the control group, the patients in the 200mg qd.2 group were treated with cilostazol from 1 week before operation to 6 months after operation. The clinical efficacy, platelet aggregation rate, hemodynamic indexes and adverse drug reactions were compared between the two groups. Results after treatment, the total effective rates of the experimental group and the control group were 85.71% (24 / 28 cases) and 54.55% (6 / 11 cases), respectively. The difference was statistically significant (P0.05). After treatment, 璇曢獙緇勫拰瀵圭収緇勭殑琛，

本文編號(hào)：2069000